Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is -24.52% as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
KLRA Return on Invested Capital (ROIC) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON INVESTED CAPITAL (ROIC)
-24.52%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
+31.24%
vs the sector median at left
Kailera Therapeutics, Inc.
Market Cap
$1.40B
Return on Invested Capital (ROIC)
-24.52%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Return on Invested Capital (ROIC)
-34.46%
TTM Avg
-51.53%
3Y Avg
-88.71%
5Y Avg
-79.79%
Market Cap
$1.40B
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Return on Invested Capital (ROIC)
5.22%
TTM Avg
4.86%
3Y Avg
3.97%
5Y Avg
3.44%
Market Cap
$1.42B
Return on Invested Capital (ROIC)
47.55%
TTM Avg
-5.71%
3Y Avg
-17.68%
5Y Avg
-14.30%
Market Cap
$1.42B
Return on Invested Capital (ROIC)
-53.48%
TTM Avg
-44.88%
3Y Avg
-46.83%
5Y Avg
-39.47%
Market Cap
$1.37B
Return on Invested Capital (ROIC)
-99.35%
TTM Avg
-175.72%
3Y Avg
-121.81%
5Y Avg
-100.94%
Market Cap
$1.44B
Return on Invested Capital (ROIC)
0.59%
TTM Avg
0.35%
3Y Avg
-0.10%
5Y Avg
-0.25%
Market Cap
$1.45B
Return on Invested Capital (ROIC)
16.83%
TTM Avg
6.43%
3Y Avg
6.32%
5Y Avg
5.53%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | -24.52% | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -34.46% | -51.53% | -88.71% | -79.79% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 5.22% | 4.86% | 3.97% | 3.44% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 47.55% | -5.71% | -17.68% | -14.30% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | -53.48% | -44.88% | -46.83% | -39.47% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -99.35% | -175.72% | -121.81% | -100.94% |
| Certara, Inc. (CERT)vs › | $1.44B | 0.59% | 0.35% | -0.10% | -0.25% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 16.83% | 6.43% | 6.32% | 5.53% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | -28.63% | -6.26% | -69.26% | -69.26% |
ROIC
-24.5%
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | -24.52% |
